<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00352560</url>
  </required_header>
  <id_info>
    <org_study_id>CV131-235</org_study_id>
    <nct_id>NCT00352560</nct_id>
  </id_info>
  <brief_title>Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF)</brief_title>
  <official_title>Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      The main purpose of the study is to compare the mean AERP between treatment groups based on
      the hypothesis that in subjects with paroxysmal AF, Irbesartan prevents electrophysiological
      remodeling resulting in a prolonged atrial effective refractory period relative (AERP) to
      placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Irbesartan effect on duration of Atrial Effective Refractory Period (AERP) in paroxysmal AF (PAF) patients.</measure>
    <time_frame>The measures are taken after 31 days of irbesartan treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Irbesartan effect on A Function RP</measure>
    <time_frame>The measures are taken after 31 days of irbesartan treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Irbesartan effect on atrial conduction intervals after basal &amp; extra-stimuli, in PAF patients</measure>
    <time_frame>The measures are taken after 31 days of irbesartan treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Refractoriness dispersion</measure>
    <time_frame>The measures are taken after 31 days of irbesartan treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan</intervention_name>
    <description>Tablets, Oral, 300 mg, once daily, 30 days.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Avapro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets, Oral, 0 mg, once daily, 30 days.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recurrent PAF with indication for catheter ablation

        Exclusion Criteria:

          -  Struct. Cardiopathy

          -  Mitral valve disease

          -  VEF&lt;40%

          -  Myocardiopathy

          -  LVH

          -  cardiac surgery

          -  AF reversible

          -  QT c&gt;450

          -  Recent MI/stroke, severe HTN

          -  Requirement of ACEI/ARBs

          -  Coronary synd., HTA, liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Angel Sanchez Zamorano, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Department, Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2006</study_first_submitted>
  <study_first_submitted_qc>July 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2006</study_first_posted>
  <disposition_first_submitted>February 15, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>February 15, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 17, 2010</disposition_first_posted>
  <last_update_submitted>February 15, 2010</last_update_submitted>
  <last_update_submitted_qc>February 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2010</last_update_posted>
  <keyword>Patients with Paroxysmal Atrial Fibrillation (PAF)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

